Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Corporate Presentation.

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 23, 2023 6:54pm

289 Views

Post# 35241030

RE:RE:RE:RE:Corporate Presentation.

No changes to Slide 16.

Minor changes as Johnny63 posted on Stocktwits:

Pg3 Remove "Cash Runway"

Pg4 Pt3 "De-risk" -> "to Advance"

Pg5 Remove "Compelling"

Pg13 "Would" -> "Could"

Pg23 "How Pela enables" -> "How Pela may enable"

Pg31 "Strong Intellectual" -> Robust Intellectual"
Patents 243 -> 240 "24 US" -> "21 US"

Pg 34 "900+ intravenously" -> "1000+ intavenously"

Pg 39 "200,000 cases" -> "180,000 cases"

<< Previous

Bullboard Posts

Next >>

Yukon agency detects cyanide near Victoria Gold's Eagle mine